• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[10-Year mortality, disease progression, and treatment-related side effects in men with localized prostate cancer from the ProtecT Randomised Controlled Trial, analyzed according to treatment received].

作者信息

Spohn Simon K B, Grosu Anca-Ligia

机构信息

Universitätsklinikum Freiburg - Klinik für Strahlenheilkunde, Robert-Koch-Straße 3, 79106, Freiburg, Deutschland.

出版信息

Strahlenther Onkol. 2021 Jul;197(7):651-654. doi: 10.1007/s00066-021-01789-y. Epub 2021 May 7.

DOI:10.1007/s00066-021-01789-y
PMID:33963439
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8219589/
Abstract
摘要

相似文献

1
[10-Year mortality, disease progression, and treatment-related side effects in men with localized prostate cancer from the ProtecT Randomised Controlled Trial, analyzed according to treatment received].[根据接受的治疗对ProtecT随机对照试验中局限性前列腺癌男性患者的10年死亡率、疾病进展及治疗相关副作用进行分析]
Strahlenther Onkol. 2021 Jul;197(7):651-654. doi: 10.1007/s00066-021-01789-y. Epub 2021 May 7.
2
Re: Ten-Year Mortality, Disease Progression, and Treatment-Related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.回复：来自 ProtecT 随机对照试验的局限性前列腺癌男性患者根据接受的治疗的十年死亡率、疾病进展及治疗相关副作用
J Urol. 2020 May;203(5):882-883. doi: 10.1097/JU.0000000000000779.02. Epub 2020 Feb 13.
3
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.局部晚期前列腺癌男性患者的短期雄激素抑制和放疗与中期雄激素抑制和放疗，联合或不联合唑来膦酸治疗（TROG 03.04 RADAR）：一项随机、3 期、析因试验的 10 年结果。
Lancet Oncol. 2019 Feb;20(2):267-281. doi: 10.1016/S1470-2045(18)30757-5. Epub 2018 Dec 19.
4
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330].《根据接受的治疗，ProtecT随机对照试验中局部前列腺癌男性的十年死亡率、疾病进展及治疗相关副作用》的勘误[《欧洲泌尿外科杂志》77卷（2020年）320 - 330页]
Eur Urol. 2020 Sep;78(3):e139-e143. doi: 10.1016/j.eururo.2020.05.030. Epub 2020 Jul 3.
5
PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.PCASTt/SPCG - 17 - 前列腺癌主动监测随机试验：原理与设计
BMJ Open. 2019 Aug 22;9(8):e027860. doi: 10.1136/bmjopen-2018-027860.
6
7
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.前列腺癌干预与观察试验：退伍军人事务部/美国国立癌症研究所/医疗保健研究与质量局合作研究项目#407（PIVOT）：一项随机对照试验的设计及基线结果，该试验比较了根治性前列腺切除术与对临床局限性前列腺癌男性进行观察等待的效果。
Contemp Clin Trials. 2009 Jan;30(1):81-7. doi: 10.1016/j.cct.2008.08.002. Epub 2008 Aug 23.
8
Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions.前列腺癌检测与治疗试验的结果是否适用于接受根治性前列腺切除术的当代前列腺癌患者？来自两个高容量欧洲机构的结果。
Eur Urol Focus. 2019 Jul;5(4):545-549. doi: 10.1016/j.euf.2017.10.013. Epub 2017 Nov 17.
9
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.度他雄胺在局限性前列腺癌管理中的应用：REDEEM 随机、双盲、安慰剂对照试验。
Lancet. 2012 Mar 24;379(9821):1103-11. doi: 10.1016/S0140-6736(11)61619-X. Epub 2012 Jan 24.
10
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.前列腺癌早期行前列腺切除术与观察治疗的随访研究。
N Engl J Med. 2017 Jul 13;377(2):132-142. doi: 10.1056/NEJMoa1615869.

本文引用的文献

1
Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in GaPSMA-11 PET images of patients with primary prostate cancer.在原发性前列腺癌患者的GaPSMA-11 PET图像中发现隐匿性——视觉上不可检测的前列腺内肿瘤病变的患病率、特征及基于放射组学特征的检测
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1987-1997. doi: 10.1007/s00259-020-05111-3. Epub 2020 Nov 18.
2
Surrogate Endpoints in Localized Prostate Cancer.局限性前列腺癌的替代终点。
Cancer J. 2020 Jan/Feb;26(1):48-52. doi: 10.1097/PPO.0000000000000422.
3
Multiparametric MRI and radiomics in prostate cancer: a review.前列腺癌中的多参数磁共振成像与放射组学：综述
Australas Phys Eng Sci Med. 2019 Mar;42(1):3-25. doi: 10.1007/s13246-019-00730-z. Epub 2019 Feb 14.
4
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.立体定向体部放疗治疗低危和中危前列腺癌的长期疗效。
JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.
5
Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.局限性前列腺癌的放射治疗、手术或观察与3年后患者报告结局之间的关联
JAMA. 2017 Mar 21;317(11):1126-1140. doi: 10.1001/jama.2017.1704.
6
Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.19Gy单次分割高剂量率近距离放射治疗低危和中危前列腺癌男性患者的初步良好结果
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):98-106. doi: 10.1016/j.ijrobp.2016.08.011. Epub 2016 Nov 9.
7
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.局限性前列腺癌监测、手术或放疗 10 年后的结果。
N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.
8
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.常规分割与大分割高剂量调强放疗治疗前列腺癌：随机、非劣效性3期CHHiP试验的5年结果
Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20.
9
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.MR/超声融合引导活检与超声引导活检诊断前列腺癌的比较。
JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.
10
Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis.比较Gleason前列腺活检和Gleason前列腺切除术分级系统：拉希诊所医疗中心的经验及一项国际荟萃分析。
Eur Urol. 2008 Aug;54(2):371-81. doi: 10.1016/j.eururo.2008.03.049. Epub 2008 Mar 28.